Association of Pulsus Paradoxus With Obesity in Normal Volunteers
To the Editor: First termed by Adolf Kussmaul in an 1873 manuscript (1) , the physical finding of pulsus paradoxus (PP) has been described in numerous clinical situations, including constrictive pericarditis, cardiac tamponade, acute pulmonary hypertension, severe asthma, tension pneumothorax, and exacerbations of chronic obstructive pulmonary disease (2) . Originally described as the disappearance of the palpated pulse during inspiration in the setting of pericardial constriction, PP has more recently been defined as a drop in systolic blood pressure (SBP) of Ͼ10 mm Hg with inspiration. This classic physical finding is discussed at all levels of medical training and is frequently used in clinical medicine.
Obesity, defined as a body mass index (BMI) Ͼ30 kg/m 2 , is a condition affecting over 30% of the U.S. population and is a global epidemic (3) . In obese patients, the compressive effects of increased abdominal girth on the chest wall and diaphragm might increase the work of breathing. We hypothesized that this exaggerated respiratory effort might lead to PP in otherwise healthy obese patients. Accordingly, we performed a prospective study to investigate the relationship between obesity and PP in patients undergoing elective cardiac catheterization.
Adult patients presenting for elective cardiac catheterization were prospectively studied for the presence of PP. These were patients with no known or suspected pericardial or pulmonary diseases by complete history and chart review. Inclusion criteria were: adult patients undergoing elective cardiac catheterization who consented to participate in the study. Exclusion criteria were: 1) any known cause of PP, to include history of chronic obstructive pulmonary disease, active or chronic pericardial diseases, active asthma exacerbation, or use of any bronchodilating medications; 2) urgent need for catheterization (e.g., ST-segment elevation myocardial infarction or hemodynamic instability); 3) right ventricular infarction; 4) recent pulmonary embolism; 5) pregnancy; or 6) decompensated heart failure.
On the day of cardiac catheterization, a physical examination was performed to exclude the presence of pulmonary or pericardial disease. Height, weight, and body circumferences at the umbilical and xiphoid levels were measured. A limited two-dimensional transthoracic echocardiogram was performed to exclude occult pericardial effusion and to assess for structural changes consistent with constrictive pericardial disease. No patient was noted to have occult pericardial effusion or significant structural enlargement of the heart chambers. Pulsus paradoxus was first measured noninvasively with sphygmomanometry and then invasively assessed within 1 h at the time of cardiac catheterization. By convention, a PP value of Ͼ10 mm Hg was considered abnormal. With a manual sphygmomanometer, repeated measurements of PP were taken in the supine position during normal resting tidal respirations until a single consistent value was determined. Invasive arterial pressure recordings were obtained via a standard coronary arteriographic catheter placed in the ascending aorta, recording for 5 to 10 respiratory cycles at 6.25 mm/s paper speed during normal resting tidal respirations. The change in SBP from inspiration to expiration was manually measured by an investigator unaware of the patients' BMI. An average of the SBP change over a minimum of five respiratory cycles was recorded as the PP value for each patient. All study patients were in a regular rhythm.
The prespecified primary analysis was the prevalence of an abnormal PP value, defined as Ͼ10 mm Hg in the obese (BMI Ͼ30 kg/m 2 ) versus the non-obese (BMI Յ30 kg/m 2 ) study patients. Assuming a prevalence of obesity of 50% and a 5% prevalence of PP in non-obese subjects, the study of 100 patients was powered to detect a 20% difference in the prevalence of an abnormal PP between the obese and non-obese groups. The t test for independent groups was used for continuous variables, the chi-square test was used for comparison of categorical variables, and the Fisher exact test was used to evaluate the differences in gender between the two groups. Bivariate correlations between invasive PP values and abdominal girth (xiphoid and umbilical), body surface area, and BMI were performed with the Pearson correlation coefficient. Multivariate analysis was performed by multivariate linear regression. Table 1 demonstrates the characteristics and results for the obese and non-obese patients. The prevalence of an abnormal PP value (Ͼ10 mm Hg) was significantly higher in obese compared with non-obese patients (Fig. 1A) . Measured invasively, 46% of obese patients had PP versus 20% of non-obese patients (p ϭ 0.012, odds ratio [OR] 3.3, 95% confidence interval [CI] 1.4 to 8.1). Measured non-invasively, 20% of the obese patients had PP versus 1.6% of the non-obese patients (p ϭ 0.013, OR 15.5, 95% CI 1.8 to 132.0). With an alternate invasive criterion for PP defined as a 9% inspiratory drop in SBP (4), obesity was significantly associated with PP (OR 5.9, 95% CI 2.0 to 17.7, p ϭ 0.002). The mean PP value was higher in the obese versus non-obese subjects with either invasive (10.1 Ϯ 2.1 vs. 7.8 Ϯ 1.5, p ϭ 0.002) or non-invasive methods (7.4 Ϯ 3.6 vs. 5.1 Ϯ 2.1, p ϭ 0.001) (Fig. 1B) . The PP values were significantly correlated with BMI (r ϭ 0.28, p ϭ 0.005), abdominal girth at the umbilical level (r ϭ 0.33, p ϭ 0.001), and xiphoid level (r ϭ 0.27, p ϭ 0.006). In multivariate analysis, umbilical girth was the strongest predictor of an elevated PP value.
Our study finds that the classic teaching of a PP value Ͼ10 mm Hg as an indicator of a pericardial or pulmonary disease process should also include obesity as a commonly associated finding. Other than case examples (5), this is the first study that systematically demonstrates a relationship between obesity and the increased prevalence of PP. This has clinical implications when dyspneic obese patients are evaluated for pericardial or pulmonary diseases. Failure to recognize this association might lead to misdiagnosis, unnecessary procedures, and additional hospital admissions (e.g., the obese asthmatic patient with dyspnea and a PP value Ͼ14).
Our study calls into question the accepted value of 10 mm Hg as the cutoff between an abnormal and normal PP value in obese patients. This analysis suggests that in using non-invasive sphygmomanometric methods, a value up to 16 mm Hg might be seen in otherwise healthy obese patients. By invasive measurements, the PP values exceeded 10 mm Hg in almost 50% of the obese patients and 20% of the non-obese patients. The question of PP values in disease states has been invasively studied in patients with known pericardial tamponade. In one of the largest series of patients with known pericardial tamponade, Reddy and Curtiss (4) proposed different criteria for PP consisting of an absolute inspiratory change of 12 mm Hg or Ͼ9% inspiratory drop in SBP. Applying these invasive criteria to our population without pericardial tamponade, we also found them to demonstrate an association between PP and obesity.
In summary, this study has shown that, with non-invasive or invasive assessment, an "abnormal" PP value is seen in a substantial proportion of individuals with a BMI exceeding 30 kg/m obesity. Higher thresholds are needed to avoid false positive diagnoses in obese patients with suspected pulmonary or pericardial diseases. Further study involving diseased and healthy obese populations is needed to fully define the optimal diagnostic values for an abnormal PP.
Diabetes Lowers Six-Minute Walk Test Performance in Heart Failure
To the Editor: Tibb et al. (1) have recently observed that patients with diabetes mellitus and left ventricular systolic dysfunction (LVSD) have a lower peak oxygen uptake ṗ VO 2 than patients with LVSD alone. Peak oxygen uptake provides important information on risk stratification and can be used to guide management (2). However, tests involve cycling-or walking-based protocols of increasing speed, gradient, or resistance, are not well tolerated in some patients with LVSD. Equipment for measuring metabolic gas exchange is expensive and cumbersome, and availability of trained staff is limited. The six-minute walk test (6-MWT) is an alternative and widely used method of assessing functional capacity; it is simple and cost effective to perform, it is safe because patients are self-paced during exertion, and previous reports suggest it is a reliable test provided it is well standardized in patients with heart failure (3). However, to our knowledge the impact of diabetes mellitus on 6-MWT performance has not been investigated previously.
Patients were recruited from a local community heart failure clinic; inclusion criteria were: stable medical therapy and evidence of LVSD, defined as a left ventricular ejection fraction (LVEF) of Ͻ40%. Exclusion criteria were: inability to walk without assistance from another person (not including mobility aids), chronic obstructive pulmonary disease (COPD) of at least moderate severity (1-s forced expiratory volume Ͻ70% of predicted, exertional angina, systolic blood pressure Ͼ160 mm Hg or diastolic blood pressure Ͼ90 mm Hg, participation in an exercise training program, and active tobacco use. Severe renal dysfunction was defined as an estimated glomerular filtration rate of Ͻ30 ml·min·1.73 m 2 ). The Hull and East Riding Ethics Committee approved the study, and all patients provided informed consent for participation. Patients who met the inclusion/exclusion criteria underwent clinical history and physical examination, together with electrocardiogram, echocardiogram, and routine blood samples. Glycosylated hemoglobin was measured in all patients. The 6-MWT was conducted following a standardized protocol after usual medication (4) . A flat obstaclefree corridor, with chairs placed at either end, was used. Patients were instructed to walk as far as possible, turning 180°every 15 m in the allotted time.
The 6-MWT performance was compared in diabetics and nondiabetics using the independent-samples t test. To explore the relation between 6-MWT and potential predictor variables, candidate variables were assessed using univariate and multivariable regression. For the final statistical model, the goodness-of-fit was assessed by calculating the explained variance and by plotting the residuals. A multivariable building process was used to identify the "best set" of predictor variables using routinely collected data, including diabetic state, hemoglobin, N-terminal portion of probrain natriuretic peptide (NT-proBNP), hypertension, ischemic heart disease (IHD), severe renal impairment, atrial fibrillation (AF), LVEF, and glycosylated hemoglobin.
We recruited our patients using the same process as Tibb et al. (1) . We first identified 256 patients with chronic heart failure (CHF) and diabetes among the 756 patients with LVEF of Ͻ40% in our clinic. We then matched these patients for age and sex to the remaining 500 nondiabetic patients. Patients were case-matched to the nearest single decimal place. We found age and gender matches for 88 patients, who were selected as our patient cohort. The 6-MWT performance was lower in diabetic (238 Ϯ 124 m) than in nondiabetic patients (296 Ϯ 131 m) (p ϭ 0.005) (Fig. 1) . Figure 1 . Six-minute walk test (6-MWT) performance in diabetic and nondiabetic patients with left ventricular systolic dysfunction. Median, interquartile range, and outliers are shown. *Significant difference in 6-MWT performance between diabetics and nondiabetics (p ϭ 0.005).
